News / Taiwan / cnyes
Pei-Er Biomedical Reports 164.71% YoY Revenue Growth for August
Health Technology · Biotechnology · cnyes · 2026-09-08
6949
Pei-Er Biomedical (6949) announced August revenue of NT$6.5 million, marking a significant 164.71% year-over-year increase and strong monthly growth.
What Happened
Revenue Performance: Pei-Er Biomedical (6949) reported August 2026 revenue of NT$6.5 million, representing a robust 164.71% increase compared to the same period last year. The company also saw a significant month-over-month surge of 157.78%.
Cumulative Results: For the first eight months of 2026, the company's cumulative revenue reached NT$24.33 million. This reflects a cumulative year-over-year growth rate of 4.21%.
Stock and Market Sentiment: The stock is currently trading at NT$60.4, outperforming the broader biotechnology sector index. Over the past five trading days, institutional investors have net bought 400 shares, with foreign investors accounting for a net purchase of 627 shares.
Outlook: The company's strong monthly revenue growth has attracted investor attention. Market participants are advised to monitor future earnings reports to assess the sustainability of this growth trajectory.